.png)
Genomic screening is transforming prenatal and neonatal care, offering new insights and challenges in equal measure. Our latest report, "Precision from the start: Balancing progress and principles in prenatal and neonatal care," dives into these advancements and the ethical dilemmas they present.
This webinar, hosted by Sano CEO Dr. Patrick Short and featuring Dr. Wendy Chung, Dr. Holly Peay, and Kira Dineen, offered a deep dive into the latest advancements in newborn screening, showcasing how cutting-edge genetic technologies are paving the way for a new era in medical care for our youngest patients. The link to the full webinar is here; a brief summary is below for easy reference.
The global battle against COVID-19 has shifted focus from acute infections to the lingering challenge posed by long COVID, a condition where signs and symptoms persist well beyond the initial infection. While most individuals experience a mild reaction to the virus, approximately 10% develop hypoxemic pneumonia, 3% progress to critical illness, and 28% go on to experience Long COVID.
Genetic testing offers a powerful lens through which we can understand and address a wide array of medical conditions, ranging from neurocognitive disorders in children to various cancers in adults. However, the rapid evolution of genomic technologies and the increasing demand for genetic testing bring to the forefront the complexities involved in interpreting genetic results. This issue is becoming increasingly pertinent for both healthcare providers and patients.
This webinar featuring Mina Frost, General Counsel for Sano Genetics, provides an insightful overview of the legal and ethical intricacies involved in precision medicine. Mina expertly explores the complexities of patient privacy, data protection, and the regulatory landscape that govern precision medicine.
Recently, our team had the pleasure of attending the 16th Annual Patient Recruitment and Retention Summit, a hallmark event in the field of clinical research and patient advocacy. Hosted in an intimate, knowledge-sharing environment, this summit brought together experts from across the globe to share insights, strategies, and innovations aimed at enhancing patient involvement in clinical research. We were proud to sponsor a booth, which served as a hub for discussions, networking, and sharing our contributions to the field. In this blog, we’ll share the themes that rose to the top in our discussions.
In observance of Rare Disease Day, our latest episode of the Genetics Podcast presents a fascinating conversation with John Matthews, who was recently promoted to Chief Medical Officer at ReCode Therapeutics. This special episode not only commemorates the day dedicated to raising awareness for rare diseases but also showcases the innovative strides being made in the field of genetic medicine for the diagnosis and treatment of rare diseases.
In our latest whitepaper, "Beyond the bench: The role of patient empowerment in shaping precision medicine research," we examine how patient involvement is transforming the field of genomics- and biomarker-driven research. In highlighting the shift towards patient-centric models, we emphasise the importance of including patient insights in the development of new treatments.
In today's digital age, scientists and medical professionals are harnessing the power of healthcare data to unravel the genetic foundations of various diseases. But despite the growing portfolio of precision medicines, their integration into healthcare systems is not without its hurdles. This blog explores the challenges and opportunities of integrating precision medicine into healthcare systems.
In the ever-evolving world of healthcare and scientific research, the rapid growth of genomic data stands out as both a remarkable achievement and a formidable challenge. Our new report, "Scaling genomic data: Addressing the storage, analysis, and accessibility hurdles of large-scale genomic data," sheds light on the complexities of managing this vast ocean of information that holds the key to unlocking the future of personalised medicine.